Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - A randomised comparative study

Journal Francais d'Ophtalmologie

Volumn 37, Issue 8, 2014, Pages 589-598

  Amrane, M ^a   Creuzot Garcher, C ^b   Robert, P Y ^c   Ismail, D ^a   Garrigue, J S ^a   Pisella, P J ^d   Baudouin, C ^e,f,g  

^a Novagali Pharma   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d CHU BRETONNEAU   (France)

^e CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Cationic emulsion; Dry eye; Tear film

Indexed keywords

CATIONORM; DRUG COMBINATION; DYE; EMULSION; EYE DROPS; FLUORESCEIN; POLYVINYL ALCOHOL; POVIDONE;

ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC USE; DRUG COMBINATION; DRUG EFFECTS; DRY EYE SYNDROMES; EMULSION; FEMALE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; LACRIMAL FLUID; MALE; MIDDLE AGED; MULTICENTER STUDY; PHARMACOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; TREATMENT OUTCOME;

ADMINISTRATION, OPHTHALMIC; AGED; DRUG COMBINATIONS; DRY EYE SYNDROMES; EMULSIONS; FEMALE; FLUORESCEIN; HUMANS; LISSAMINE GREEN DYES; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POLYVINYL ALCOHOL; POVIDONE; SEVERITY OF ILLNESS INDEX; TEARS; TREATMENT OUTCOME;

EID: 84908200905     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2014.05.001     Document Type: Conference Paper

References (36)

1. Epidemiology of dry eye. Report of the Epidemiology Sub-committee of the Dry Eye WorkShop (DEWS). Ocul Surf2007;5:93-107.
2. Baudou in C, Aragona P, Messmer E, Tomlinson A, Calonge M,Boboridis K, et al. Role of hyperosmolarity in the pathogenesisand management of dry eye disease: proceedings of the OCEANGroup meeting. Ocul Surf 2013;4:246-58.
3. Schaumberg A, Sullivan DA, Buring JE, Dana MR. Prevalenceof dry eye syndrome among US women. Am J Ophthalmol2003;136:318-26.
4. Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, Rigeade MC,Brouquet Y, Bassols A, et al. Severe impairment of health-related quality of life in patients suffering from ocular surfacediseases. J Fr Ophtalmol 2008;31:369-78.
5. T he definition and classification of dry eye disease: report ofthe Definition and Classification Subcommittee of the Interna-tional Dry Eye WorkShop. Ocul Surf 2007;5:75-92.
6. Rolando M, Geerling G, Dua HS, Bentez-del-Castillo JM,Creuzot-Garcher C. Emerging treatment paradigms of ocular surface disease: proceedings of the Ocular Surface Workshop.Br J Ophthalmol 2010;94:i1-9.
7. Gayton JL. Etiology, preva lence, and treatment of dry eye dis-ease. Clin Ophthalmol 2009;3:405-12.
8. Management and therapy of dry eye disease: report of themanagement and therapy Subcommittee of the InternationalDry Eye WorkShop (DEWS). Ocul Surf 2007;5:163-78.
9. Vandamme TF. Microemulsions as ocular drug delivery systems:recent developments and future challenges. Prog Retin Eye Res2002;21:15-34.
10. Rieg er G. Lipid-containing eye drops: a step closer to naturaltears. Ophthalmologica 1990;201:206-12.
11. Tiffany JM. Lipid-containing eye drops. Ophthalmologica1991;203:47-9.
12. Murube J, Paterson A, Murube E. Classification of artifi-cial tears. I: composition and properties. Adv Exp Med Biol1998;438:693-704.
13. Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Suc-cessfully improving ocular drug delivery using the cationicnanoemulsion, Novasorb. J Drug Deliv 2012;2012:604204.
14. Royle L,Matthews E,Corfield A,Berry M,Rudd PM DwekRA,et al. Glycan structures of ocular surface mucins inman rabbit and dog display species differences. Glycoconj J2008 25, 763-73.
15. Rabinovich YI, Vakarelski IU, Brown SC, Singh PK, MoudgilBM. Mechanical and thermodynamic properties of surfactantaggregates at the solid-liquid interface. J Colloid Interface Sci2004;270:29-36.
16. Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmo-protectants on hyperosmolar stress in cultured human cornealepithelial cells. Cornea 2008;27:574-9.
17. Korb DR, Scaffidi RC, Greiner JV, Kenyon KR, Herman JP, BlackieCA, et al. The effect of two novel lubricant eye drops on tearfilm lipid layer thickness in patients with dry eye symptoms.Optom Vis Sci 2005;82:594-601.
18. Scaffidi RC, Korb DR. Comparison of the efficacy of two lipidemulsion eye drops in increasing tear film lipid layer thickness.Eye Contact Lens 2007;33:38-44.
19. Rolando M, Brezzo G, Giordano P, Campagna P, Burlando S,Calabria G. The effect of different benzalkonium chlorideconcentrations on human normal ocular surface: a controlledprospective impression cytology study. In: Van Bijsterweld OP,Lemp MA, Spinelli D, editor s. The Lacrimal System. Amsterdam:Kagler & Ghedini; 1991. p. 89-91.
20. Debbasch C, Pisella PJ, De Saint Jean M, Rat P, Warnet JM,Baudouin C. Mitochondrial activity and glutathione injury inapoptosis i nduced by unpreserved and preserved betablock-ers on Chang conjunctival cells. Invest Ophthalmol Vis Sci2001;42:2525-33.
21. Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, MaoZ, Riancho L, Faure MO, et al. Reduction of quaternaryammonium-induced ocular surface toxicity by emulsions: anin vivo study in rabbits. Mol Vis 2008;14:204-16.
22. Liang H, Baudouin C, Faure MO, Lambert G, Bri gnole-Baudouin F. Comparison of the ocular tolerability of alatanoprost cationic emulsion versus conventional formulationsof prostaglandins: an in vivo toxicity assay. Mol Vis 2009;15:1690-9.
23. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, AzarDT, et al. Dysfunctional tear syndrome: a Delphi approach totreatment recommendations. Cornea 2006;25:900-7.
24. Lemp MA, Hamill JR. Factors affecting tear film break-up innormal eyes. Arch Ophthalmol 1973;89:103-5.
25. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunc-tival staining in the context of other dry eye tests. Cornea2003;22:640-50.
26. Van Bijsterveld OP. Diagnostic tests in the sicca syndrome. ArchOphthalmol 1969;82:10-4.
27. McMonnies CW, Chapman-Davies A. Assessment of conjunctivalhyperemia in contact lens wearers. Part I. Am J Optom PhysiolOpt 1987;64:246-50.
28. Hardin JW, Hilbe JM. Generalized linear models and extensions.College Station, TX: Stata Press; 2001.
29. Design and conduct of clinical trials. Report of the Clinical TrialsSubcommittee of the International Dry Eye WorkShop (DEWS).Ocul Surf 2007;5:153-62.
30. Ousler GW, Gomes PJ, Welch D, Abelson MB. Methodologiesfor the study of ocular surface disease. Ocul Surf 2005;3:143-54.
31. Savini G, Prabhawasat P, Kojima T, Grueterich M, Espana E,Goto E. The challenge of dry eye diagnosis. Clin Ophthalmol2008;2:31-55.
32. Foulks GN. Challenges and pitfalls in clinical trials of treat-ments for dry eye. Ocul Surf 2003;1:20-30.
33. Foulks GN. The correlation between the tear film lipid layerand dry eye disease. Surv Ophthalmol 2007;52:369-74.
34. McCann LC, Tomlinson A, Pearce EI, Papa V. Effectiveness ofartificial tears in the management of evaporative dry eye.Cornea 2012;31:1-5.
35. Cuevas M, Gonzá lez-García MJ, Castellanos E, Quispaya R,Parra PD, Ferná ndez I, et al. Correlations among symptoms,signs, and clinical tests in evaporative-type dry eye diseasecaused by Meibomian gland dysfunction (MGD). Curr Eye Res2012;37:855-63.
36. Nichols KK,Foulks GN,Bron AJ,Glasgow BJ,Dogru M,Tsub-ota K,et al. The international workshop on Meibomian glanddysfunction: executive summary. Invest Ophthalmol Vis Sci2011 52, 1922-9.